Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.

Abstract

Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards "me too" drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is common these years. The molecules are withdrawn at various… (More)
DOI: 10.1016/j.apsb.2013.12.003

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Blog articles referencing this paper

Slides referencing similar topics